The risk or severity of adverse effects can be increased when Reserpine is combined with Tetrodotoxin. The risk or severity of adverse effects can be increased when Seratrodast is combined with Flumethasone. The risk or severity of adverse effects can be increased when Oxprenolol is combined with Mannitol. The metabolism of Riluzole can be decreased when combined with Azithromycin. The serum concentration of Gentamicin can be decreased when it is combined with Sulbactam. The serum concentration of Diethylstilbestrol can be decreased when it is combined with Enalapril. The risk or severity of adverse effects can be increased when Bromocriptine is combined with Aliskiren. Methylprednisolone may increase the hypokalemic activities of Hydroflumethiazide. The metabolism of Nilvadipine can be decreased when combined with Dihydroergotamine. The serum concentration of Betamethasone can be increased when it is combined with Tibolone. The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxprenolol. Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Amphetamine may increase the hypotensive activities of Perindopril. The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Nafamostat. The serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Fosphenytoin. Zaltoprofen may increase the hyperkalemic activities of Drospirenone. The risk or severity of adverse effects can be increased when Triflupromazine is combined with Dexbrompheniramine. The serum concentration of Clobetasone can be decreased when it is combined with Phenytoin. Desvenlafaxine may increase the hyponatremic activities of Hydrochlorothiazide. The risk or severity of adverse effects can be increased when Eprosartan is combined with Quinapril. The risk or severity of adverse effects can be increased when Timolol is combined with Epibatidine. Ketorolac may increase the anticoagulant activities of Fluindione. Alfuzosin may increase the hypotensive activities of Moexipril. Labetalol may increase the orthostatic hypotensive activities of Prazosin. Nadroparin may increase the hyperkalemic activities of Olmesartan. The serum concentration of Ondansetron can be decreased when it is combined with Cyproterone acetate. The risk or severity of adverse effects can be increased when Salicylic acid is combined with Desoxycorticosterone Pivalate. The risk or severity of adverse effects can be increased when Cilazapril is combined with Phenylbutazone. The risk or severity of adverse effects can be increased when Nortriptyline is combined with Scopolamine. Mefloquine may increase the QTc-prolonging activities of Tetrabenazine. The risk or severity of adverse effects can be increased when Metipranolol is combined with Clevidipine. The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Benperidol. The metabolism of Nitrendipine can be increased when combined with Nafcillin. Yohimbine may decrease the antihypertensive activities of Manidipine. The metabolism of Alogliptin can be decreased when combined with Fluvoxamine. The risk or severity of adverse effects can be increased when Aloxiprin is combined with Parnaparin. The risk or severity of adverse effects can be increased when Methocarbamol is combined with Flunarizine. The risk or severity of adverse effects can be increased when Fluprednidene is combined with Hepatitis B Vaccine (Recombinant). Choline magnesium trisalicylate may decrease the excretion rate of Neomycin which could result in a higher serum level. Pseudoephedrine may decrease the sedative activities of Isothipendyl. Xylometazoline may increase the hypotensive activities of Macitentan. The risk or severity of adverse effects can be increased when Nebivolol is combined with Riociguat. Benmoxin may increase the hypoglycemic activities of Pioglitazone. The metabolism of Alogliptin can be decreased when combined with Dronedarone. Nebivolol may increase the bradycardic activities of Proscillaridin. The metabolism of Caffeine can be decreased when combined with Dihydroergotamine. The serum concentration of Dyphylline can be decreased when it is combined with Methohexital. The serum concentration of Glimepiride can be increased when it is combined with Ranitidine. The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorothiazide. The metabolism of Losartan can be decreased when combined with Nefazodone. The risk or severity of adverse effects can be increased when Salicylamide is combined with Budesonide. Mesalazine may decrease the antihypertensive activities of Benazepril. Hydralazine may increase the hypotensive activities of Metyrosine. The risk or severity of adverse effects can be increased when Pargyline is combined with Dobutamine. The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Tixocortol. The serum concentration of Diclofenac can be increased when it is combined with Tolbutamide. The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Levetiracetam. The metabolism of Raloxifene can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Anisodamine. The risk or severity of adverse effects can be increased when Bromocriptine is combined with Lidocaine. The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tinoridine. The metabolism of Brompheniramine can be decreased when combined with Cimetidine. Hydroxyamphetamine may decrease the sedative activities of Pheniramine. The serum concentration of Quinethazone can be increased when it is combined with Ipratropium bromide. The serum concentration of Cobimetinib can be increased when it is combined with Sulfisoxazole. The therapeutic efficacy of Dinoprost can be decreased when used in combination with Ketoprofen. The risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclopenthiazide. The metabolism of Temazepam can be decreased when combined with Rosiglitazone. Lisinopril may increase the hypotensive activities of Oxprenolol. Pirlindole may increase the hypotensive activities of Ramipril. The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitroglycerin. The metabolism of Alogliptin can be decreased when combined with Bortezomib. The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin. Clonidine may increase the hypotensive activities of Unoprostone. The metabolism of Encainide can be decreased when combined with Artemether. The risk or severity of adverse effects can be increased when Pentamidine is combined with Xylometazoline. The serum concentration of Zalcitabine can be increased when it is combined with Simeprevir. The risk or severity of adverse effects can be increased when Meprobamate is combined with Levodopa. The metabolism of Indomethacin can be increased when combined with Rifampicin. The risk or severity of adverse effects can be increased when Verapamil is combined with Papaverine. Diclofenac may increase the neuroexcitatory activities of Gemifloxacin. The risk or severity of adverse effects can be increased when Reserpine is combined with Levobupivacaine. The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Atorvastatin. The risk or severity of adverse effects can be increased when Oxycodone is combined with Methylphenobarbital. The bioavailability of Hydrocortisone can be decreased when combined with Sodium bicarbonate. Colesevelam can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy. The metabolism of Triamcinolone can be decreased when combined with Isavuconazonium. The metabolism of Ramelteon can be decreased when combined with Erythromycin. The risk or severity of adverse effects can be increased when Tiotropium is combined with Tramadol. The serum concentration of Pirarubicin can be decreased when it is combined with Azlocillin. Atenolol may decrease the bronchodilatory activities of Levosalbutamol. The risk or severity of adverse effects can be increased when Mometasone is combined with Mefloquine. The risk or severity of adverse effects can be increased when Amcinonide is combined with Mefloquine. The risk or severity of adverse effects can be increased when Nitrazepam is combined with Methylphenobarbital. The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Zaltoprofen. The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Bendroflumethiazide. Opipramol may increase the vasopressor activities of Phenylephrine. Proscillaridin may decrease the cardiotoxic activities of Verteporfin. The metabolism of Flunisolide can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Lorazepam is combined with Clobazam. The metabolism of Tinidazole can be decreased when combined with Telaprevir. The risk or severity of adverse effects can be increased when Pindolol is combined with Nesiritide. The risk or severity of adverse effects can be increased when Candesartan is combined with Mizoribine. The metabolism of Bupivacaine can be decreased when combined with Atazanavir. The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Miconazole. The metabolism of Salicylic acid can be decreased when combined with Irbesartan. The risk or severity of adverse effects can be increased when Methaqualone is combined with Nortriptyline. The serum concentration of Tamsulosin can be decreased when it is combined with Tocilizumab. The metabolism of Methyltestosterone can be decreased when combined with Isavuconazonium. The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Propacetamol. The risk or severity of adverse effects can be increased when Rescinnamine is combined with Pirfenidone. The risk or severity of adverse effects can be increased when Mebendazole is combined with Metronidazole. The risk or severity of adverse effects can be increased when Prazosin is combined with Furosemide. The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluorometholone. The risk or severity of adverse effects can be increased when Tolazoline is combined with Azilsartan medoxomil. The metabolism of Dexfenfluramine can be decreased when combined with Ketoconazole. The risk or severity of adverse effects can be increased when Ibuprofen is combined with Formestane. Salicylic acid may decrease the antihypertensive activities of Carteolol. The serum concentration of Ranolazine can be increased when it is combined with Azithromycin. The metabolism of Acetylsalicylic acid can be decreased when combined with Ketoconazole. Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. The therapeutic efficacy of Pentazocine can be decreased when used in combination with Naltrexone. The risk or severity of adverse effects can be increased when Difluocortolone is combined with Galantamine. The risk or severity of adverse effects can be increased when Candesartan is combined with Olsalazine. Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital. Bufexamac may increase the neuroexcitatory activities of Nalidixic Acid. The bioavailability of Prednisone can be decreased when combined with Aluminum hydroxide. The metabolism of Zomepirac can be increased when combined with Pentobarbital. The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Carbinoxamine. The risk or severity of adverse effects can be increased when Quinapril is combined with Acebutolol.